Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Debt to Equity (2016 - 2023)

Amicus Therapeutics filings provide 14 years of Debt to Equity readings, the most recent being $0.12 for Q2 2023.

  • On a quarterly basis, Debt to Equity rose 4.92% to $0.12 in Q2 2023 year-over-year; TTM through Jun 2023 was $0.12, a 4.92% increase, with the full-year FY2022 number at $0.17, up 183.06% from a year prior.
  • Debt to Equity hit $0.12 in Q2 2023 for Amicus Therapeutics, down from $0.12 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.41 in Q2 2020 to a low of $0.03 in Q4 2020.
  • Median Debt to Equity over the past 5 years was $0.12 (2023), compared with a mean of $0.18.
  • Biggest five-year swings in Debt to Equity: skyrocketed 1500.53% in 2019 and later crashed 89.95% in 2020.
  • Amicus Therapeutics' Debt to Equity stood at $0.31 in 2019, then plummeted by 89.95% to $0.03 in 2020, then skyrocketed by 97.86% to $0.06 in 2021, then surged by 183.06% to $0.17 in 2022, then crashed by 33.04% to $0.12 in 2023.
  • The last three reported values for Debt to Equity were $0.12 (Q2 2023), $0.12 (Q1 2023), and $0.17 (Q4 2022) per Business Quant data.